GET DAILY SIGNALSJohnson & Johnson (JNJ) Eyes +12% Move Toward $310 Technical Level
Key Takeaways
- The $310 objective is not an analyst consensus. It is a technical milestone drawn from public discussion of Johnson & Johnson (JNJ) testing record highs, and it sits about 12% above the latest close.
- The stock closed at $276.22 on Nov 6, 2026, just below its 52-week high of $282.02 reached in late October.
- The average of roughly 17 current Wall Street 12-month price targets is about $288, with a range of about $260 to $320 — implying only about 4% upside, too modest to serve as a meaningful "reach" target.
- Reaching $310 would require a roughly 12% advance, a substantial move that would take the shares decisively above their prior record high and the $300 round number.
- Support comes from a robust new-product cycle in oncology and immunology, recent FDA approvals, and solid 2026 growth guidance; key risks are Stelara patent erosion, litigation, and an elevated multiple.
- For additional context, see the Major News, Today's Price Move, Forecast, and Earnings pages.
- Explore Trending AI Robots to see automated strategies monitoring this and other names.
How the $310 Target Came Into View
Johnson & Johnson operates through two main segments: Innovative Medicine for pharmaceuticals and MedTech for devices. It is a single stock rather than an ETF. With most Wall Street targets clustered only modestly above the current price, I am using a technical milestone as the objective instead of stretching for a consensus figure.
Individual targets range from UBS at $320 and Scotiabank at $305 down to Stifel at $260, with the average sitting near $288. That leaves only about 4% implied upside on average, or roughly 6% when focusing solely on the higher targets. Because neither meets a clear 10% threshold, the discussion centers on the $310 level that often appears in market commentary as the shares test record territory above the prior high and the $300 psychological barrier.
Current Position and the Path Ahead
At the Nov 6 close of $276.22, the $310 level represents roughly 12.2% upside. The shares have roughly doubled from the November 2025 low near $185 and carry a market cap around $665 billion. After touching the 52-week high of $282.02 in late October, the stock pulled back following an initially soft quarterly report before recovering on pipeline updates, including new Impella data and FDA approval for RYBREVANT in head and neck cancer. Clearing $310 would mean reclaiming the prior high, moving past $300, and sustaining the move on earnings strength rather than multiple expansion alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Factors That Could Support Further Gains
The company posted about 6% sales growth and 8.1% adjusted EPS growth in 2025, with 2026 guidance pointing to roughly 6.7% sales growth and 6.9% EPS growth at the midpoint. Oncology has been a bright spot, led by Darzalex and Carvykti, while electrophysiology delivered double-digit gains. A steady stream of new products is helping offset the impact from Stelara’s loss of exclusivity. Recent regulatory wins and device data strengthen the pipeline story, and the roughly 1.9% dividend yield can appeal to income-oriented investors during volatile periods.
Obstacles That Could Limit Progress
Stelara erosion and the broader wave of patent expirations remain a structural challenge, requiring the company to show that new launches can consistently replace lost revenue. Ongoing talc and other liability matters continue to weigh on both finances and perception. The trailing P/E near 40x incorporates one-time items, yet some analysts question whether the current premium leaves much room for further re-rating. A disappointing quarterly report, such as the early November print, can quickly shift sentiment, and the shares remain exposed to any rotation out of defensive healthcare names.
Key Technical Levels to Watch
Immediate resistance lies at the 52-week high of $282.02, followed by the $300 level. A sustained move above $282 would open the door to the $300–$310 zone. On the downside, the $265–$266 area, which includes recent lows and the 50-day moving average near $266, offers initial support, while the 200-day moving average near $248 serves as a longer-term floor.
Time Horizon and Items Worth Monitoring
Analyst targets typically look out about 12 months. Investors should track the next earnings release and any updated guidance, changes in individual price targets, oncology and immunology data readouts, progress on product launches, and developments in the talc litigation. Shifts in interest-rate expectations and sector flows into or out of healthcare can also affect valuation multiples. From what I see, these catalysts will matter more than any single price level.
AI Daily Buy/Sell Signals
AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. For a name like Johnson & Johnson that sits near multi-year highs, these signals can highlight shifts in momentum ahead of manual review. I have found them useful for spotting new setups and monitoring existing positions more efficiently.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JNJ in upward trend: 10-day moving average moved above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Indicator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement